Cullinan Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
CGEM$11.31+4.7%Stored close · as of Nov 6, 2026
Contents
Consolidated Balance Sheets
(in thousands, except share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $74,228 | $98,434 |
| Short-term investments | 358,783 | 368,633 |
| Prepaid expenses and other current assets | 12,710 | 13,124 |
| Total current assets | 445,721 | 480,191 |
| Property and equipment, net | 913 | 989 |
| Operating lease right-of-use assets | 2,336 | 2,543 |
| Other assets | 460 | 459 |
| Total assets | $449,430 | $484,182 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,707 | $2,493 |
| Accrued expenses and other current liabilities | 16,889 | 24,204 |
| Operating lease liabilities, current | 1,329 | 1,440 |
| Total current liabilities | 21,925 | 28,137 |
| Long-term liabilities: | ||
| Operating lease liabilities, net of current portion | 1,840 | 2,150 |
| Total liabilities | 23,765 | 30,287 |
| Commitments and contingencies (Note 10) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 647,500 shares issued and outstanding as of March 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 43,065,645 and 42,900,083 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 4 | 4 |
| Additional paid-in capital | 663,997 | 654,685 |
| Accumulated other comprehensive loss | (331) | (129) |
| Accumulated deficit | (238,005) | (200,857) |
| Total Cullinan stockholders' equity | 425,665 | 453,703 |
| Noncontrolling interests | — | 192 |
| Total stockholders' equity | 425,665 | 453,895 |
| Total liabilities and stockholders' equity | $449,430 | $484,182 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.